Rituximab and minimal change nephrotic syndrome: a therapeutic option (Q37879578)

24 August 2017

1 reference

title

Rituximab and minimal change nephrotic syndrome: a therapeutic option (English)

1 reference

24 August 2017

1 reference

1 reference

Takashi Takei

1

1 reference

24 August 2017

Kosaku Nitta

series ordinal

2

1 reference

24 August 2017

publication date

26 May 2011

1 reference

Clinical and experimental nephrology

24 August 2017

published in

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

641-647

1 reference

The characteristics of relapse in adult-onset minimal-change nephrotic syndrome

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Recent approaches to the pathogenesis of minimal-change nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Clinical use of rituximab in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Fatal pulmonary fibrosis after rituximab administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0465-6

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

21 January 2018

1 reference

12 December 2020

Steroid-sensitive nephrotic syndrome: from childhood to adulthood

1 reference

12 December 2020

Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome

1 reference

12 December 2020

Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

1 reference

12 December 2020

Rituximab efficiency in children with steroid-dependent nephrotic syndrome

1 reference

12 December 2020

Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Pharmacodynamics of Rituximab in Kidney Allotransplantation

1 reference

12 December 2020

In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.

1 reference

12 December 2020

T cells and minimal change disease

1 reference

12 December 2020

Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome

1 reference

12 December 2020

Rituximab therapy for steroid-dependent minimal change nephrotic syndrome

1 reference

12 December 2020

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

12 December 2020

Effect of single-dose rituximab on primary glomerular diseases

1 reference

12 December 2020

Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome

1 reference

12 December 2020

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

12 December 2020

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

12 December 2020

Severe ulcerative colitis after rituximab therapy

1 reference

12 December 2020

Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse

1 reference

12 December 2020

Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.

1 reference

12 December 2020

Nephrotic syndrome in the elderly.

1 reference

12 December 2020

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

1 reference

12 December 2020

Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

10.1007/S10157-011-0465-6

Identifiers

DOI

1 reference

24 August 2017

1 reference